The group wants to improve on its own Welireg in a new phase 3 trial.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
After a delay, the Alpha-3 study faces an April futility analysis.
A first-in-human trial of PRT12396 starts next month.
Early data are coming with the KRAS G12D degrader ARV-806.
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
Clinical trial entrants include projects from Gyala, Beijing Biotech and Neowise.
After reporting stellar data at ASH, Terns is acquired for $6.7bn.
